Atsuo Yoshino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Atsuo Yoshino has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Koichiro Sumi
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo 173‐8610, Japan
11 shared publicationsShun Yamamuro
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo 173‐8610, Japan
10 shared publicationsEmiko Sano
9 shared publicationsHiroyuki Hara
Department of Functional Morphology, Nihon University School of Medicine, Tokyo 173‑8610, Japan
9 shared publicationsSodai Yoshimura
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo 173‐8610, Japan
9 shared publications- Shun Yamamuro
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan
7 shared publications
Latest Publications
- Open Access
- 16 August 2026
- Published by Elsevier in SSRN Electronic Journal
Regeneration of the dura mater using photocrosslinked gelatin hydrogel with enhanced membrane formation
The dura mater and arachnoid membrane are essential for maintaining central nervous system (CNS) homeostasis, and their disruption during neurosurgical procedures can lead to complications such as cerebrospinal fluid (CSF) leakage and infection. This study evaluated the efficacy and safety of a visible light–induced photocrosslinked gelatin hydrogel for dural reconstruction using a rat durotomy model. Animals were divided into three groups: control, collagen-based artificial dura (DuraGen®), and hydrogel treatment. Histological, immunohistochemical, Western blot, and real-time quantitative PCR analyses were performed at 1, 3, and 7 days postoperatively. The hydrogel demonstrated rapid in situ gelation and remained at the application site for up to 7 days before complete absorption by day 14. Histological analysis revealed effective formation of a membrane-like structure at the dural defect, with significantly greater thickness in the hydrogel group compared to the DuraGen® group at days 3 and 7. No cystic changes suggestive of pseudomeningocele were observed. Immunohistochemical staining and Western blot analysis showed no significant increase in microglial or astrocytic activation in the hydrogel group. Furthermore, inflammatory cytokine expression, including TNF-α, IL-1β, and IL-6, was not elevated compared to controls. These findings indicate that photocrosslinked gelatin hydrogel promotes early and robust dural repair without inducing significant inflammatory or cytotoxic responses. This material shows promise as a novel artificial dura substitute for neurosurgical applications.
- 16 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRegeneration of the dura mater using photocrosslinked gelatin hydrogel with enhanced membrane formation
The dura mater and arachnoid membrane are essential for maintaining central nervous system (CNS) homeostasis, and their disruption during neurosurgical procedures can lead to complications such as cerebrospinal fluid (CSF) leakage and infection. This study evaluated the efficacy and safety of a visible light–induced photocrosslinked gelatin hydrogel for dural reconstruction using a rat durotomy model. Animals were divided into three groups: control, collagen-based artificial dura (DuraGen®), and hydrogel treatment. Histological, immunohistochemical, Western blot, and real-time quantitative PCR analyses were performed at 1, 3, and 7 days postoperatively. The hydrogel demonstrated rapid in situ gelation and remained at the application site for up to 7 days before complete absorption by day 14. Histological analysis revealed effective formation of a membrane-like structure at the dural defect, with significantly greater thickness in the hydrogel group compared to the DuraGen® group at days 3 and 7. No cystic changes suggestive of pseudomeningocele were observed. Immunohistochemical staining and Western blot analysis showed no significant increase in microglial or astrocytic activation in the hydrogel group. Furthermore, inflammatory cytokine expression, including TNF-α, IL-1β, and IL-6, was not elevated compared to controls. These findings indicate that photocrosslinked gelatin hydrogel promotes early and robust dural repair without inducing significant inflammatory or cytotoxic responses. This material shows promise as a novel artificial dura substitute for neurosurgical applications.
- Open Access
- 16 March 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
Retrospective epidemiological study on cervical fracture dislocation in adolescents using the Diagnosis Procedure Combination database in Japan
This was a retrospective study using the Diagnosis Procedure Combination (DPC) database. Using a large national database, we aimed to investigate the epidemiology, treatment patterns, and outcomes of cervical fracture dislocation (CFD) among adolescents. There have been numerous clinical studies on CFD in adults. However, the current lack of studies on adolescent CFD is a clinically relevant research gap that urgently needs to be addressed. Among 4,653 inpatients who were identified to have a definitive diagnosis of CFD from 2010 to 2021 from the DPC database, we extracted the medical data of 84 adolescent inpatients (aged 11-18 years). CFD in adolescent inpatients was rare, accounting for only 1.8% of all patients with CFD in the DPC database. Complications occurred in 31 patients (36.9%), and mortality rate was 9.5%. Of eight patients who died, four were complicated by traumatic brain injury. Polytrauma was found in 32 patients (38.1%), and its incidence was significantly higher in those with mental disorders (p <0.001). The proportion of patients who were discharged home was significantly lower in those with mental disorders than in those without mental disorders (p =0.01). This epidemiological study provided new insights into adolescent CFD using real-world data. Future research should focus on the evaluation of long-term functional prognosis and development of preventive strategies and improved treatments for CFD in adolescent patients.
- 16 March 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
Open AccessRetrospective epidemiological study on cervical fracture dislocation in adolescents using the Diagnosis Procedure Combination database in Japan
This was a retrospective study using the Diagnosis Procedure Combination (DPC) database. Using a large national database, we aimed to investigate the epidemiology, treatment patterns, and outcomes of cervical fracture dislocation (CFD) among adolescents. There have been numerous clinical studies on CFD in adults. However, the current lack of studies on adolescent CFD is a clinically relevant research gap that urgently needs to be addressed. Among 4,653 inpatients who were identified to have a definitive diagnosis of CFD from 2010 to 2021 from the DPC database, we extracted the medical data of 84 adolescent inpatients (aged 11-18 years). CFD in adolescent inpatients was rare, accounting for only 1.8% of all patients with CFD in the DPC database. Complications occurred in 31 patients (36.9%), and mortality rate was 9.5%. Of eight patients who died, four were complicated by traumatic brain injury. Polytrauma was found in 32 patients (38.1%), and its incidence was significantly higher in those with mental disorders (p <0.001). The proportion of patients who were discharged home was significantly lower in those with mental disorders than in those without mental disorders (p =0.01). This epidemiological study provided new insights into adolescent CFD using real-world data. Future research should focus on the evaluation of long-term functional prognosis and development of preventive strategies and improved treatments for CFD in adolescent patients.
- Open Access
- 14 November 2025
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 13 (4) , e81240040
Perampanel Effects on Sleep in Epilepsy Patients: A Pilot Case Series on Its Therapeutic Potential for Sleep Disorders
Background Sleep disorders are common among individuals with epilepsy, often leading to disturbances in sleep patterns and architecture. Certain anti-seizure medications adversely affect sleep independently of their anti-seizure effects. Objective This study aims to examine the impact of perampanel (PER) on sleep disorders in patients with epilepsy. Methods The effects of adjunctive PER therapy on circadian rhythm and daytime sleepiness were evaluated in epilepsy patients with comorbid sleep disorders. Twenty-one eligible patients were included, excluding those with liver failure or psychological disorders. This pilot case series assessed participants using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale. PER blood concentrations were measured. Patients were selected based on baseline PSQI scores ≥6 (mean 11.57 ± 2.77). Results After 3 months of PER administration, the mean global PSQI score significantly improved to 6.71 ± 5.00 (p<0.01). Improvements were observed in PSQI components: C1 (sleep quality), C2 (sleep latency), and C6 (frequency of sleep medication use). A strong positive correlation was found between changes in PSQI scores (delta-PSQI = post-PER − pre-PER score) and PER blood concentrations (r = 0.71, p<0.01). Conclusion Adjunctive PER therapy significantly improved subjective sleep quality in epilepsy patients with comorbid sleep disorders. The correlation between the magnitude of improvements and PER blood concentration suggests a dose–response relationship. These findings indicate that PER may be a beneficial therapeutic option for managing sleep disturbances in this population and support the need for further investigation in larger, controlled studies.
- 14 November 2025
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 13 (4) , e81240040
Open AccessPerampanel Effects on Sleep in Epilepsy Patients: A Pilot Case Series on Its Therapeutic Potential for Sleep Disorders
Background Sleep disorders are common among individuals with epilepsy, often leading to disturbances in sleep patterns and architecture. Certain anti-seizure medications adversely affect sleep independently of their anti-seizure effects. Objective This study aims to examine the impact of perampanel (PER) on sleep disorders in patients with epilepsy. Methods The effects of adjunctive PER therapy on circadian rhythm and daytime sleepiness were evaluated in epilepsy patients with comorbid sleep disorders. Twenty-one eligible patients were included, excluding those with liver failure or psychological disorders. This pilot case series assessed participants using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale. PER blood concentrations were measured. Patients were selected based on baseline PSQI scores ≥6 (mean 11.57 ± 2.77). Results After 3 months of PER administration, the mean global PSQI score significantly improved to 6.71 ± 5.00 (p<0.01). Improvements were observed in PSQI components: C1 (sleep quality), C2 (sleep latency), and C6 (frequency of sleep medication use). A strong positive correlation was found between changes in PSQI scores (delta-PSQI = post-PER − pre-PER score) and PER blood concentrations (r = 0.71, p<0.01). Conclusion Adjunctive PER therapy significantly improved subjective sleep quality in epilepsy patients with comorbid sleep disorders. The correlation between the magnitude of improvements and PER blood concentration suggests a dose–response relationship. These findings indicate that PER may be a beneficial therapeutic option for managing sleep disturbances in this population and support the need for further investigation in larger, controlled studies.
- Open Access
- 31 August 2024
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
- Vol. 18 (4) , 508-513
Effects of early surgery for cervical fracture dislocation on 30-day mortality using the Japanese Diagnosis Procedure Combination database
Study Design: Retrospective study of data abstracted from the Diagnosis Procedure Combination (DPC) database.Purpose: This study aimed to investigate the effects of surgery in the early phase.Overview of Literature: The optimal timing of surgery for cervical fracture dislocation (CFD) remains unclear because only a few clinical studies with approximately 100 patients have been published.Methods: This study included 4,653 adult patients with a definitive diagnosis of CFD from the DPC database. The database contains nationwide inpatient data collected from >1,000 acute care hospitals in Japan. The DPC database contains information regarding hospitalization, such as diagnosis, treatment, medical history, complications, and hospitalization outcomes. This study identified 460 pairs of patients after one-to-one propensity-score matching (PSM). Treatment outcomes were compared between patients who underwent surgery for CFD within 72 hours (early group) and later (delayed group) after admission. The main outcomes included 30-day mortality, inhospital death, and major complications. The secondary outcomes were improvement in the Barthel index, length of hospital stay, and discharged home rate.Results: After adjusting for PSM, the early group had a significantly higher 30-day mortality rates than the delayed group (3.0% vs. 0.4%, p=0.006). In the multivariate logistic regression analysis after PSM, the early group was associated with an increased risk of 30-day mortality (odds ratio, 8.05; 95% confidence interval, 2.15–5.26; p=0.007).Conclusions: This study indicated that early surgery for CFD resulted in increased 30-day mortality.
- 31 August 2024
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
- Vol. 18 (4) , 508-513
Open AccessEffects of early surgery for cervical fracture dislocation on 30-day mortality using the Japanese Diagnosis Procedure Combination database
Study Design: Retrospective study of data abstracted from the Diagnosis Procedure Combination (DPC) database.Purpose: This study aimed to investigate the effects of surgery in the early phase.Overview of Literature: The optimal timing of surgery for cervical fracture dislocation (CFD) remains unclear because only a few clinical studies with approximately 100 patients have been published.Methods: This study included 4,653 adult patients with a definitive diagnosis of CFD from the DPC database. The database contains nationwide inpatient data collected from >1,000 acute care hospitals in Japan. The DPC database contains information regarding hospitalization, such as diagnosis, treatment, medical history, complications, and hospitalization outcomes. This study identified 460 pairs of patients after one-to-one propensity-score matching (PSM). Treatment outcomes were compared between patients who underwent surgery for CFD within 72 hours (early group) and later (delayed group) after admission. The main outcomes included 30-day mortality, inhospital death, and major complications. The secondary outcomes were improvement in the Barthel index, length of hospital stay, and discharged home rate.Results: After adjusting for PSM, the early group had a significantly higher 30-day mortality rates than the delayed group (3.0% vs. 0.4%, p=0.006). In the multivariate logistic regression analysis after PSM, the early group was associated with an increased risk of 30-day mortality (odds ratio, 8.05; 95% confidence interval, 2.15–5.26; p=0.007).Conclusions: This study indicated that early surgery for CFD resulted in increased 30-day mortality.
- Open Access
- 21 October 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (6) , 1-12
Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells
Patients with glioblastoma frequently suffer epileptic seizures and often require anticonvulsant therapy during the treatment course. The present study investigated four common antiepileptic drugs, perampanel, carbamazepine (CBZ), sodium valproate (VPA) and levetiracetam (LEV), which are expected to have antitumor effects, and determined the most beneficial drug for the treatment of malignant glioma by comparing antitumor effects such as inhibition of cell proliferation and suppression of migration and invasion (using Transwell assays). The inhibition of cell growth was investigated using six malignant glioma cell lines (A‑172, AM‑38, T98G, U‑138MG, U‑251MG and YH‑13). Significant inhibition of cell proliferation was observed in all six cell lines treated with perampanel, three cell lines treated with CBZ, four cell lines treated with VPA and two cell lines treated with LEV at the therapeutic blood concentration levels for the drugs to be used as antiepileptics. Further antitumor effects in combination with temozolomide were investigated using T98G and U‑251MG cell lines, and were confirmed in both cell lines with perampanel and in T98G cells with LEV, but not observed with CBZ and VPA. Cell migration was significantly suppressed in both T98G and U‑251MG cell lines with perampanel, but not with CBZ, VPA or LEV. To investigate the mechanisms by which perampanel suppresses the migration of malignant glioma cells, the expression of mRNA related to epithelial‑mesenchymal transition following perampanel treatment was analyzed using reverse transcription‑quantitative PCR in the T98G and U‑251MG cell lines. The expression of Rac1 and RhoA, which constitute the cytoskeleton that enhances cell motility, were reduced in both cell lines. Furthermore, the expression of the mesenchymal marker N‑cadherin, which promotes cell migration and infiltration, was decreased, but the expression of the epithelial marker E‑cadherin, which strengthens cell‑cell adhesion and reduces cell motility, was increased. Furthermore, the expression of matrix metalloproteinase‑2, a proteolytic enzyme, was reduced. These effects may reduce cell motility and increase adhesion between cells, suggesting that perampanel treatment suppressed cell migration. In conclusion, the present study suggests that perampanel may be more beneficial in terms of antitumor efficacy than other antiepileptic drugs for the treatment of malignant glioma.
- 21 October 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (6) , 1-12
Open AccessAnti‑tumor effects of anti‑epileptic drugs in malignant glioma cells
Patients with glioblastoma frequently suffer epileptic seizures and often require anticonvulsant therapy during the treatment course. The present study investigated four common antiepileptic drugs, perampanel, carbamazepine (CBZ), sodium valproate (VPA) and levetiracetam (LEV), which are expected to have antitumor effects, and determined the most beneficial drug for the treatment of malignant glioma by comparing antitumor effects such as inhibition of cell proliferation and suppression of migration and invasion (using Transwell assays). The inhibition of cell growth was investigated using six malignant glioma cell lines (A‑172, AM‑38, T98G, U‑138MG, U‑251MG and YH‑13). Significant inhibition of cell proliferation was observed in all six cell lines treated with perampanel, three cell lines treated with CBZ, four cell lines treated with VPA and two cell lines treated with LEV at the therapeutic blood concentration levels for the drugs to be used as antiepileptics. Further antitumor effects in combination with temozolomide were investigated using T98G and U‑251MG cell lines, and were confirmed in both cell lines with perampanel and in T98G cells with LEV, but not observed with CBZ and VPA. Cell migration was significantly suppressed in both T98G and U‑251MG cell lines with perampanel, but not with CBZ, VPA or LEV. To investigate the mechanisms by which perampanel suppresses the migration of malignant glioma cells, the expression of mRNA related to epithelial‑mesenchymal transition following perampanel treatment was analyzed using reverse transcription‑quantitative PCR in the T98G and U‑251MG cell lines. The expression of Rac1 and RhoA, which constitute the cytoskeleton that enhances cell motility, were reduced in both cell lines. Furthermore, the expression of the mesenchymal marker N‑cadherin, which promotes cell migration and infiltration, was decreased, but the expression of the epithelial marker E‑cadherin, which strengthens cell‑cell adhesion and reduces cell motility, was increased. Furthermore, the expression of matrix metalloproteinase‑2, a proteolytic enzyme, was reduced. These effects may reduce cell motility and increase adhesion between cells, suggesting that perampanel treatment suppressed cell migration. In conclusion, the present study suggests that perampanel may be more beneficial in terms of antitumor efficacy than other antiepileptic drugs for the treatment of malignant glioma.
- Open Access
- 7 October 2022
- Published by Spandidos Publications in Oncology Letters
- Vol. 24 (6) , 1-9
Anti‑tumor effects of perampanel in malignant glioma cells
Glioblastoma has a poor prognosis even after multimodal treatment, such as surgery, chemotherapy and radiation therapy. Patients with glioblastoma frequently develop epileptic seizures during the clinical course of the disease and often require antiepileptic drugs. Therefore, agents with both antiepileptic and antitumoral effects may be very useful for glioblastoma treatment. Perampanel, an α‑amino‑3‑hydroxy‑5‑methyl‑4‑isoxazole propionic acid receptor antagonist, is an antiepileptic drug that is widely used for intractable epilepsy. The present study aimed to assess the potential antitumoral effects of perampanel using malignant glioma cell lines. The cell proliferation inhibitory effect was evaluated using six malignant glioma cell lines (A‑172, AM‑38, T98G, U‑138MG, U‑251MG and YH‑13). A dose‑dependent inhibitory effect of perampanel on cell viability was demonstrated; however, the sensitivity of cells to perampanel varied and further antitumoral effects were demonstrated in combination with temozolomide (TMZ) in certain malignant glioma cells. Furthermore, cell cycle distribution and apoptosis induction analyses were performed in T98G and U‑251MG cells using a fluorescence activated cell sorter (FACS) and the expression levels of apoptosis‑related proteins were evaluated using western blotting. No significant change was demonstrated in the proportions of cells in the G0/G1, S and G2/M phases under 1.0 µM perampanel treatment, whereas induction of apoptosis was demonstrated using FACS at 10 µM perampanel and western blotting at 1.0 µM perampanel in both glioma cell lines. Overexpression of SERPINE1 may be related to poor prognosis in patients with gliomas. The combination of 1.0 µM perampanel and 5.0 µM tiplaxtinin, a SERPINE1 inhibitor, demonstrated further reduced cell viability in perampanel‑resistant U‑138MG cells, which have high expression levels of SERPINE1. These results indicated that the antitumor effect of perampanel may not be expected for malignant gliomas with higher expression levels of SERPINE1. The findings of the present study suggested that the antiepileptic drug perampanel may also have an antitumor effect through the induction of apoptosis, which is increased when combined with TMZ in certain malignant glioma cells. These findings also suggested that SERPINE1 expression may be involved in perampanel susceptibility. These results may lead to new therapeutic strategies for malignant glioma.
- 7 October 2022
- Published by Spandidos Publications in Oncology Letters
- Vol. 24 (6) , 1-9
Open AccessAnti‑tumor effects of perampanel in malignant glioma cells
Glioblastoma has a poor prognosis even after multimodal treatment, such as surgery, chemotherapy and radiation therapy. Patients with glioblastoma frequently develop epileptic seizures during the clinical course of the disease and often require antiepileptic drugs. Therefore, agents with both antiepileptic and antitumoral effects may be very useful for glioblastoma treatment. Perampanel, an α‑amino‑3‑hydroxy‑5‑methyl‑4‑isoxazole propionic acid receptor antagonist, is an antiepileptic drug that is widely used for intractable epilepsy. The present study aimed to assess the potential antitumoral effects of perampanel using malignant glioma cell lines. The cell proliferation inhibitory effect was evaluated using six malignant glioma cell lines (A‑172, AM‑38, T98G, U‑138MG, U‑251MG and YH‑13). A dose‑dependent inhibitory effect of perampanel on cell viability was demonstrated; however, the sensitivity of cells to perampanel varied and further antitumoral effects were demonstrated in combination with temozolomide (TMZ) in certain malignant glioma cells. Furthermore, cell cycle distribution and apoptosis induction analyses were performed in T98G and U‑251MG cells using a fluorescence activated cell sorter (FACS) and the expression levels of apoptosis‑related proteins were evaluated using western blotting. No significant change was demonstrated in the proportions of cells in the G0/G1, S and G2/M phases under 1.0 µM perampanel treatment, whereas induction of apoptosis was demonstrated using FACS at 10 µM perampanel and western blotting at 1.0 µM perampanel in both glioma cell lines. Overexpression of SERPINE1 may be related to poor prognosis in patients with gliomas. The combination of 1.0 µM perampanel and 5.0 µM tiplaxtinin, a SERPINE1 inhibitor, demonstrated further reduced cell viability in perampanel‑resistant U‑138MG cells, which have high expression levels of SERPINE1. These results indicated that the antitumor effect of perampanel may not be expected for malignant gliomas with higher expression levels of SERPINE1. The findings of the present study suggested that the antiepileptic drug perampanel may also have an antitumor effect through the induction of apoptosis, which is increased when combined with TMZ in certain malignant glioma cells. These findings also suggested that SERPINE1 expression may be involved in perampanel susceptibility. These results may lead to new therapeutic strategies for malignant glioma.
- 22 January 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 181, 46-54
Anti-inflammatory effect of P2Y1 receptor blocker MRS2179 in a rat model of traumatic brain injury
- 22 January 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 181, 46-54
Anti-inflammatory effect of P2Y1 receptor blocker MRS2179 in a rat model of traumatic brain injury
- 1 November 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (11) , 106078
Clinical Study of Cerebral Ischemia in Moyamoya Disease from the View of Development of the Anterior Choroidal Artery
- 1 November 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (11) , 106078
Clinical Study of Cerebral Ischemia in Moyamoya Disease from the View of Development of the Anterior Choroidal Artery
- Open Access
- 1 September 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 25
Investigation of factors that contribute to the outcome of endoscopic transsphenoidal surgery as reviewed from our own cases
- 1 September 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 25
Open AccessInvestigation of factors that contribute to the outcome of endoscopic transsphenoidal surgery as reviewed from our own cases